Regulation of the Hippo pathway and implications for anticancer drug development.
about
A Review: Molecular Aberrations within Hippo Signaling in Bone and Soft-Tissue SarcomasMolecular classification of gastric cancer: Towards a pathway-driven targeted therapyYAP and TAZ: a nexus for Hippo signaling and beyondHippo/YAP pathway for targeted therapyHippo Pathway in Organ Size Control, Tissue Homeostasis, and CancerMutant p53 Protein and the Hippo Transducers YAP and TAZ: A Critical Oncogenic Node in Human Cancers.The essential role of YAP O-GlcNAcylation in high-glucose-stimulated liver tumorigenesisThe Hippo pathway in disease and therapy: cancer and beyondDownstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinomaMolecular profiling and computational network analysis of TAZ-mediated mammary tumorigenesis identifies actionable therapeutic targets.Oncoprotein YAP regulates the spindle checkpoint activation in a mitotic phosphorylation-dependent manner through up-regulation of BubR1.The hippo pathway effector YAP regulates motility, invasion, and castration-resistant growth of prostate cancer cells.Cell growth density modulates cancer cell vascular invasion via Hippo pathway activity and CXCR2 signaling.Ski regulates Hippo and TAZ signaling to suppress breast cancer progression.A YAP/TAZ-induced feedback mechanism regulates Hippo pathway homeostasisTargeting the Central Pocket in Human Transcription Factor TEAD as a Potential Cancer Therapeutic Strategy.The Hippo pathway effectors YAP and TAZ promote cell growth by modulating amino acid signaling to mTORC1.Wnt activated β-catenin and YAP proteins enhance the expression of non-coding RNA component of RNase MRP in colon cancer cells.Active YAP promotes pancreatic cancer cell motility, invasion and tumorigenesis in a mitotic phosphorylation-dependent manner through LPAR3Fat4 suppression induces Yap translocation accounting for the promoted proliferation and migration of gastric cancer cellsCell density regulates cancer metastasis via the Hippo pathway.YAP controls transcriptional elongation through CKD9 recruitment for proximal pause release: "Hippo-thetical", new therapeutic targets?Targeting αvβ3 and αvβ5 integrins inhibits pulmonary metastasis in an intratibial xenograft osteosarcoma mouse model.Structural dissection of Hippo signaling.Hippo signaling in epithelial stem cells.Targeting YAP in malignant pleural mesothelioma.Angiomotin decreases lung cancer progression by sequestering oncogenic YAP/TAZ and decreasing Cyr61 expression.Hippo pathway deregulation: implications in the pathogenesis of haematological malignancies.Signaling Cross Talk between TGF-β/Smad and Other Signaling Pathways.Kidney-specific knockout of Sav1 in the mouse promotes hyperproliferation of renal tubular epithelium through suppression of the Hippo pathway.Repression of YAP by NCTD disrupts NSCLC progression.Elevated expression of Par3 promotes prostate cancer metastasis by forming a Par3/aPKC/KIBRA complex and inactivating the hippo pathwayDownregulation of MiR-31 stimulates expression of LATS2 via the hippo pathway and promotes epithelial-mesenchymal transition in esophageal squamous cell carcinoma.Identification of MST1 as a potential early detection biomarker for colorectal cancer through a proteomic approach.In Vitro Validation of the Hippo Pathway as a Pharmacological Target for Canine Mammary Gland Tumors.Tissue inhibitor of metalloproteinase-1 promotes cell proliferation through YAP/TAZ activation in cancer.The dark side of hippo signaling: A cancer promoter role.Oncogenic kinase-induced PKM2 tyrosine 105 phosphorylation converts non-oncogenic PKM2 to a tumor promoter and induces cancer stem-like cells.The Role of Hippo Pathway in Cancer Stem Cell Biology.Oncogenic Signaling Pathways in The Cancer Genome Atlas.
P2860
Q26782842-014FEF6C-55DE-4E62-AC70-47F185500F92Q26798420-AA1608DE-69EA-4BC4-B77C-464DDD2F6CEEQ28085636-B3521A37-A2BA-49DC-8A3D-6D45AD0A76D9Q28088294-77882D3F-7673-4E1B-B936-556E63CE36CEQ28269498-F42F4615-E926-4969-AE4C-8398D1C4E358Q30354662-EFEE33D4-3359-4059-A559-DE6F1C38C196Q33654365-E56F192D-79DE-4588-87FF-C51249FAC2F2Q33937666-47584F36-388D-4EBF-9FF9-7E4DF46B7FAFQ34246014-B42DE8D8-F60D-4CB8-B45F-FEA9F55A5B3AQ35068051-1011AD09-BF1C-4C32-8B1D-7B84D3AB1BD1Q35172929-6CFD9CEF-ECA4-4BFD-A29C-19A06F361AF8Q35214708-35961E00-7780-467A-B02D-202109D9B090Q35577502-53CBB79F-A8E4-482A-9141-207C175852AAQ35688452-DA65D853-5E8B-4242-A9AD-663AB228C7E1Q35829995-00BFD88F-9735-460E-9679-35763AB4117DQ36320570-7D30593F-D465-4F1B-BA79-A2677C5B9EF2Q36350091-180829BD-661A-4B1A-9A5F-84707FE5D275Q36544177-D0707798-7399-4E87-8D97-EAE70740456EQ36546544-6DD31EB4-8FCF-4FF0-B702-F3234F1D6618Q36843790-076558D1-ED4A-4D34-A287-73FB24097889Q37158424-CABE4B2C-1E98-4D89-B77D-6E3F76130DA3Q37187741-594BF2E1-537A-4567-8130-368A8930C041Q37688207-4B51CE3F-74EB-4B0E-9F93-0A372280472DQ38283342-AD4A1EBB-4CE5-4A7E-8E10-95F350236E41Q38283344-B0D09F42-0046-4C2A-95A4-8728F8F7C325Q38704895-2A456C72-4828-40B2-B880-8E059E17FF23Q38941672-F47414FF-5710-4B39-B565-EF7F8A96901EQ38995148-55154FEF-2208-4582-8A89-5F69DE4A1583Q39005862-C7144E01-10FA-4D95-9B81-3477908DDD3EQ40778207-44148391-E038-4BE7-8653-B5D9704AB66FQ42315519-56C03DEE-CE6E-492D-82A6-32C89B77C410Q42373532-D601FC67-69C5-47F1-8088-BF3548AC3A81Q47101112-846D8B5E-C8DF-428E-87CC-DA275DA1655AQ47174489-18AD07CF-290F-4CD6-B495-53385C3DFE78Q47664161-2E50C72A-24FD-4764-98B8-AD0130C9B171Q47780433-2B241311-BB69-4114-81FA-45E7A80C2FA5Q48335680-DFC63261-4B18-40B4-866D-6EF33C10CA3CQ50027361-FEACC130-29E8-4B5A-9655-745C71F526FCQ50078696-C8A4E8BF-6FA1-4B5E-B70B-C7136B23C3DAQ52602404-6AA659AF-7689-435C-AF7C-2134D5AAEAC3
P2860
Regulation of the Hippo pathway and implications for anticancer drug development.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Regulation of the Hippo pathway and implications for anticancer drug development.
@en
Regulation of the Hippo pathway and implications for anticancer drug development.
@nl
type
label
Regulation of the Hippo pathway and implications for anticancer drug development.
@en
Regulation of the Hippo pathway and implications for anticancer drug development.
@nl
prefLabel
Regulation of the Hippo pathway and implications for anticancer drug development.
@en
Regulation of the Hippo pathway and implications for anticancer drug development.
@nl
P2860
P1476
Regulation of the Hippo pathway and implications for anticancer drug development.
@en
P2093
Hyun Woo Park
Kun-Liang Guan
P2860
P304
P356
10.1016/J.TIPS.2013.08.006
P577
2013-09-16T00:00:00Z